Epitranscriptomic signatures in blood: emerging biomarkers for diagnosis of diabetes and its complications

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F25%3A00641121" target="_blank" >RIV/67985823:_____/25:00641121 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.3389/fcell.2025.1656769" target="_blank" >https://doi.org/10.3389/fcell.2025.1656769</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fcell.2025.1656769" target="_blank" >10.3389/fcell.2025.1656769</a>

Result language

angličtina

Original language name

Epitranscriptomic signatures in blood: emerging biomarkers for diagnosis of diabetes and its complications

Original language description

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by chronic hyperglycemia, insulin resistance, and progressive β-cell dysfunction. Traditional biomarkers, such as fasting glucose and glycated hemoglobin (HbA1c), offer diagnostic and prognostic value but have limitations in sensitivity and predictive power for disease progression. Recent advances in molecular biology have identified epitranscriptomic modifications as potential biomarkers for T2DM, offering a novel layer of gene expression regulation through reversible RNA modifications. Dysregulation of these modifications has been implicated in insulin resistance, β-cell failure, and diabetes-related complications. Notably, altered levels of N6-methyladenosine (m6A) and its regulatory enzymes, including the eraser fat mass and obesity-associated protein (FTO) and the writer methyltransferase-like 3 (METTL3), have been detected in peripheral blood of T2DM patients, suggesting their potential as promising diagnostic markers. Similarly, circulating levels of pseudouridine (Ψ) have been associated with diabetic complications such as retinopathy and nephropathy. This review highlights the emerging role of epitranscriptomic modifications in T2DM pathophysiology and discusses their translational potential as biomarkers for early detection, disease monitoring, and personalized therapeutic strategies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Cell and Developmental Biology

ISSN

2296-634X

e-ISSN

2296-634X

Volume of the periodical

13

Issue of the periodical within the volume

21 Oct

Country of publishing house

CH - SWITZERLAND

Number of pages

8

Pages from-to

1656769

UT code for WoS article

001606289800001

EID of the result in the Scopus database

2-s2.0-105020923184